Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor for prevention of major cardiovascular events in high-risk type 2 diabetes
CTR20140893Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ticagrelor in type 2 diabetes mellitus (T2DM), atherosclerotic disease, sponsored by AstraZeneca. Started Jan 2015; status: completed.
02
Drugs
ticagrelor
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic disease
Beyond the preview
Go deeper on CTR20140893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140893.